Is Moderna a Good Healthcare Stock to Buy Now?

·3 min read

Moderna's (NASDAQ: MRNA) COVID-19 vaccine has created a multibillion-dollar revenue stream for the company, but is the massive $130 billion valuation of the business justified? In this Fool Live video clip, recorded on Oct. 4, Fool.com contributors Rachel Warren and Jason Hall discuss whether Moderna could be a smart buy despite its nosebleed-level valuation. Rachel Warren: It's funny, because I write about healthcare stocks a lot and I'm a healthcare writer here at the Fool.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting